| US benchmarks posted losses in November's first trading session on Tuesday. The Dow fell 0.2%, and the S&P 500 slid to a 0.4% loss. The Nasdaq lost 0.8%, and the Russell 2K managed to hold onto a 0.2% gain. Today, futures are uncertain ahead of the opening bell. S&P 500 contracts are currently showing a small gain of less than 0.1%. Shocking Warning: A "Nightmare Winter" is Coming... ð¨ The Elite Establishment is playing two dangerous games at once⦠They are aiming to change the way a modern economy works, by mandating a complete switch to âgreen energyâ⦠And, they're paying for it with unlimited amounts of new âpaperâ money. This is going to be really bad for a lot of peopleâbut it doesnât have to be bad for you. Making a few simple moves now could spare you from catastrophic losses down the road, but you need to get started right away. Fortunately, two investing legends have teamed up to bring you all the resources you need to make it through in one piece. See Their Full Briefing Here and Take Action Now. Job Openings Rise: Job openings grew to a seasonally-adjusted 10.7 million in September, and the data showed demand for workers continued to outpace the supply of unemployed people looking for work. Match Group Inc [MTCH] - Last Close: $43.90 Match Group is breaking out on strong earnings results. The online dating stock posted better-than-expected Q3 earnings and revenues this morning. Match's Q3 earnings came in a $0.44 per share and beat analysts' $0.41 EPS estimate.
Revenues of $810 also topped The Street's target of $795.43 million. Match also announced plans to accelerate its cost-cutting efforts in the face of increasingly challenging economic circumstances. MTCH is leading the S&P 500 with a 15.0% gain. My Take: This could be a pivot point for Match. The stock has suffered steady declines for the past 12 months, but this rally could help it break out of its funk. It's still expensive, but it could be a good entry point for a swing trade. Arcuturus Therapeutics Holdings Inc [ARCT] - Last Close: $18.28 News of a new collaboration is lifting shares of Arcuturus Therapeutics. The RMA medicines company announced early this morning that it is teaming up with CSL Seqirus to develop and sell mRNA vaccines for serious respiratory viruses. Arcuturus wil grant CSL a license to its Starr and Lunar mRNA technologies, as well as mRNA drug substance and manufacturing knowledge. In exchange, Arcuturus will receive $200 million upfront, and it could receive another $1.3 billion in development milestones and $3 billion in commercial milestones. The company says it's also entitled to a 40% net profit share for COVID-19 vaccine products and up to double-digit royalties for flu vaccines. ARCT is one of today's top performers with a 31.9% gain. My Take: This is a big deal for Arcuturus that could generate billions in revenues over the first year, but it's going to take some time before everything shakes out. The initial news is already priced in, but the deal is good reason to give ARCT a closer look. CytoSorbents Corp [CTSO] - Last Close: $1.89 Promising drug data is giving Cytosorbents a boost today. The MedTech company presented final key results from its trial of its CytoSorb blood purification technology in ICUs and cardiac surgeries. Clinical data from the trials showed that enhanced lung rest with CytoSorb+ECMO yielded a high survival rate among the sickest COVID-19 patients with refractory lung failure. In a 100-patient study, the therapy produced substantial improvements over baseline data and excellent outcomes that were reproduced in several different centers. The promising data powered CTSO to a 21.6% gain in today's premarket. My Take: The treatment data sounds promising, but this tiny biotech could have a tough road ahead of it. I'd treat this as a speculative trade at best. Chegg Inc [CHGG] - Last Close: $21.11 Chegg is moving in the wake of its quarterly report. The direct-to-student learning platform reported better-than-expected Q3 earnings results in Tuesday's after-hours, and the results are pushing shares higher this morning. Chegg generated Q3 non-GAAP earnings of $0.21 per share, which beat analysts' $0.14 per share target by 50%. Revenues of $164.7 million also topped the consensus estimate of $158.3 million. Chegg also announced it expects full-year 2022 revenues ranging from $762 million to $765 million, which surpassed analysts' $761.2 million expectation. CHGG is one of today's top movers with a 18.2% premarket gain. My Take: CHGG looks like a decent small-cap stock. It's had a rough year, but shares are slowly climbing higher. It's P/E of 10.71 looks like a bargain, and share prices may have finally bottomed out. | 